Summary

Intensive glucose-lowering therapy, defined as aiming for HbA1C levels below 7%, improves glycemic control among high-risk patients with type 2 diabetes mellitus. However, it has no long-term effect on cardiovascular outcomes in this patient population, according to findings from the Veterans Affairs Diabetes Trial [VADT].